The FDA has fast tracked development of AbbVie’s potential spinal injury drug, elezanumab, a process that will be aided by digital analysis.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,